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Crohn’s disease (CD) is a 
chronic disorder with variable 
clinical manifestations and a 
heterogeneous disease course. 
The phenotype is defined by 
age at diagnosis, location, and disease behaviour 
according to the Montreal classification[1] (Table 
1). Behaviour is categorised as the uncomplicated 
‘non-stricturing and non-penetrating’ (B1) 
phenotype, ‘stricturing’ (B2) phenotype and 
‘penetrating’ (B3) phenotype. Penetrating CD is 
also known as fistulising CD. The behaviour of 
CD tends to evolve over time to be complicated 
by the development of strictures, fistulas or 
abscesses. At diagnosis 80% of patients have 
purely inflammatory B1 luminal disease, but 
by 10 years more than half will have progressed 
to complicated B2 and B3 phenotypes, often 
requiring hospitalisation.[2,3] Ultimately 80% with 
this progression require surgery.[4]
Aggressive medical therapy with immuno-
modulators (IMMs) such as azathioprine 
or methotrexate and biologicals may alter 
this natural history and improve long-term 
outcomes, but should be introduced early in 
the disease course, before the development of 
irreversible complications.[5-7] Such strategies 
place patients at risk of adverse events, notably 
infections and malignant disease.[8,9] Population-
based studies have shown that a sizeable num-
ber of CD patients will have a benign course, 
never require surgery and never suffer a flare-
up severe enough to warrant corticosteroids,[10] 
and to subject these individuals to drugs with 
potentially serious side-effects is of concern. 
In addition, these medications (notably 
biologicals) are expensive, and access is 
limited in resource-challenged environments 
such as ours in South Africa (SA).
Several studies have analysed factors 
early in the course of CD that may predict 
future outcomes and identify those patients 
at risk of developing complicated CD and 
who would receive greatest benefit from 
early, aggressive therapy. A number of 
clinical variables have been associated 
with the subsequent development of poor-
outcome CD, notably an initial need for 
corticosteroids, age <40 years, ileocolonic 
location, stricturing behaviour, weight loss 
>5 kg and perianal disease at diagnosis.[11,12]
Several serological markers, such as anti-
Saccharomyces cerevisiae antibodies, have 
also been shown to predict disease severity, 
as have tissue granulomas.[13,14]
More recently Siegel et al.[15] developed 
a model using system dynamics analysis 
to assess the probability of developing 
a CD-related complication. This model 
included patient and disease variables, 
serological markers and medical therapies. 
They demonstrated how data can be 
transformed into a simple graph showing 
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Table 1. Classification of Crohn’s disease 
according to the Montreal classification[1]
Age at diagnosis
A1: ≤16 years






L4: Isolated upper GIT*
Behaviour




P: Perianal disease modifier†
GIT = gastrointestinal tract.
*L4 can be added to locations L1 - L3 to indicate 
coexisting upper GI disease.
†P can be added to any behaviour to indicate coexisting 
perianal disease.
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a real-time individualised probability of disease complications. 
Unfortunately serological markers are not available and are not tested 
for in our CD subjects, limiting such an approach in our setting. 
Furthermore, it is unclear whether the predictive clinical variables 
from European populations are applicable in our local setting, given 
that our patients differ from those treated in the West. Notably CD 
is more aggressive in non-Caucasians, the incidence is higher, and 
common genetic CD susceptibility mutations frequently seen in the 
developed world are absent in our clinic population.[16,17] In addition, all 
these European studies included subjects who already had complicated 
penetrating or stricturing phenotypes at diagnosis, indicating some 
degree of irreversible damage to the gastrointestinal tract. Ability to 
evaluate predictive factors for SCD in patients with uncomplicated CD 
at diagnosis would be of greater value, as these are the patients in whom 
one may realistically hope to change the natural history of the disease.
To date no study has been done in SA to analyse risk factors 
predicting poor-outcome CD in uncomplicated B1 disease at 
diagnosis. In view of the potential risk of progression to complicated 
CD over time, and the lack of local evidence regarding which patients 
are at risk, the aim of this study was to evaluate clinical and laboratory 
indices in subjects with uncomplicated CD, as well as endoscopic 
biopsy granulomas at the time of diagnosis, and the association with 
adverse disease outcomes.
Methods
The research protocol was approved by the Ethics Committee of the 
University of Cape Town.
A retrospective cohort study was conducted evaluating all patients 
diagnosed with CD (duration >5 years) in our unit to 31 December 
2011. Of 567 CD patients registered on our database, 310 were 
eligible for inclusion. We reviewed their clinical records. Patients were 
excluded if there were incomplete data at baseline (n=151), if they 
had not been seen within 12 months (n=10), if there was complex 
perianal, stricturing or penetrating CD at diagnosis (n=37), or if 
they had undergone surgical resection within 1 month of diagnosis 
(n=9). Two further subjects were excluded because their diagnosis 
was revised. Overall 84% of patients with data at diagnosis had B1 
disease. Complex perianal disease was defined according to the 
American Gastroenterology Association recommendation as ‘fistulas 
that are high intersphincteric, high transsphincteric, extrasphincteric 
or suprasphincteric, have multiple external openings, are associated 
with a perianal abscess, fistulise to adjacent organs, are associated with 
the presence of an anorectal stricture or associated with the presence 
of active rectal disease’.[18]
Severe CD (SCD) was defined (as previously described by Loly et 
al.[11] as the presence of any of the following over the entire disease 
course: ‘complex perianal disease; any colonic resection; two or more 
small-bowel resections; a single small-bowel resection more than 50 
cm in length; or construction of a definitive stoma’.
Patients were followed up from CD diagnosis until 31 December 
2011, or alternatively until the development of SCD.
The following data were collected at diagnosis and during follow-up: 
demographics, clinical and biochemical variables, histological evidence 
of granulomas, corticosteroid use, hospitalisations, surgeries, creation of 
a definitive stoma, progression from B1 to B2 or B3 phenotypes, IMMs 
or biological use, and the development of perianal fistulas.
Statistical analysis
All continuous variables evaluated were not normally distributed and 
are therefore expressed as medians and interquartile ranges (IQRs). 
Categorical variables were compared using the χ2 or Fisher’s exact test, as 
appropriate. In addition, univariate and multivariate Cox proportional 
hazard analysis was performed to identify risk factors associated with 
time to the development of SCD. Variables with p-values ≤0.2 were 
included in the multivariate model. The Kaplan-Meier method was 
used to estimate the cumulative probability of developing SCD as well as 
progression from B1 to B2 or B3 phenotypes over time.
Results
Overall, 101 subjects were eligible for inclusion in the study. The 
median age at diagnosis was 31 years (IQR 23 - 39), and 61.4% (62/101) 
were female. At diagnosis 36.6% (37/101) had isolated ileocaecal (L1) 
disease, 27.7% (28/101) isolated colonic (L2) disease and 35.6% (36/101) 
ileocolonic (L3) disease. Six patients (5.9%) also had involvement of the 
upper GIT, 13.9% (14/101) had evidence of simple perianal disease, 65.3% 
(66/101) were active cigarette smokers, 55.4% (56/101) were treated with 
corticosteroids for the first flare of disease, and 41.6% (42/101) had non-
caseating granulomas on endoscopic biopsy at diagnosis.
Overall, 33.7% of patients (34/101) developed SCD over their disease 
course. The median time to the development of SCD was 103 months 
(IQR 60 - 144). The cumulative probability of developing SCD was 
11%, 21% and 30% at 1, 5 and 10 years after diagnosis, respectively. 
Predictors at diagnosis associated with the time to development of SCD 
are presented in Table 2. After multivariate analysis, only perianal disease 
(hazard ratio (HR) 2.49; 95% confidence interval (CI) 1.14 - 5.41; p=0.02) 
and granulomas (HR 2.3; 95% CI 1.15 - 4.64; p=0.02) at diagnosis were 
independently associated with time to the development of SCD. There 
were no statistically significant differences when evaluating patients with 
or without granulomas. There was also no difference in baseline variables 
in subjects with or without perianal CD.
Kaplan-Meier curves for the development of SCD according to the 
presence or absence of these two factors are shown in Fig. 1. Sensitivity, 
specificity, positive predictive value and negative predictive value 
of a logistic regression model including these two risk factors were 
21%, 99%, 88% and 71%, respectively. Of patients with B1 disease at 
diagnosis, 42.3% progressed to B2 or B3 phenotype over time. The 
cumulative probability of developing either of these complicated 
phenotypes was 13% at 1 year, 24% at 2 years, 33% at 5 years and 43% at 
10 years. The median time to progression was 24 months (IQR 11 - 78). 
None of the baseline parameters assessed was significantly associated 
with time to B2 or B3 progression.
Forty patients (39.6%) with a B1 phenotype at diagnosis ultimately 
required a surgical resection, while 26 (25.7%) underwent two or more 
surgical resections. The presence of granulomas at diagnosis was the 
only predictor for more than one resection during follow-up (OR 4.7; 
95% CI 1.8 - 12.3; p=0.002).
Discussion
Our results are consistent with previous reports in that the majority 
of CD patients with uncomplicated B1 CD at diagnosis went on to a 
disabling disease course over time. We only included subjects with 
purely inflammatory B1 disease at diagnosis, as most patients who have 
stricturing or penetrating phenotypes or complex perianal CD would 
already be considered to have complicated disease and therefore to 
be candidates for aggressive therapy with IMMs and biologicals.[5] As 
such, predicting poor-outcome CD in these patients is not as valuable 
as in patients with uncomplicated disease, in whom the decision to start 
disease-modifying therapies has far more important consequences. 
Overall, 33.7% of our cohort developed SCD over their disease 
course. This is almost identical to the figure reported by Loly et al.[11] 
in their Liège cohort. In keeping with several other studies, perianal 
disease emerged as a strong predictor of poor-outcome CD.[12,19] Our 
analysis also revealed that endoscopic tissue biopsy granulomas at 
diagnosis were associated with earlier development of SCD and were 
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the only predictor for more than one surgical 
procedure during follow-up.
Granulomas are considered a histological 
characteristic of CD. However, in reality fewer 
than 50% of patients will have them on biopsy 
specimens, and their pathogenesis is unknown. 
Several studies evaluating poor-outcome CD 
have included granulomas in analysis, and 
although results are conflicting, most favour 
granulomas as a predictor of aggressive CD. A 
2010 meta-analysis concluded that granulomas 
appear to be associated with a higher number 
of recurrences and surgeries.[14] However, 
it is difficult to draw conclusions from this 
analysis given significant heterogeneity 
between studies. A study by Freeman[20] 
showed that the presence of granulomas was 
linked to a more complicated disease course, 
with more extensive ileocolonic and upper 
gastrointestinal tract involvement and more 
penetrating disease. In addition, Heresbach 
et al.[21] demonstrated that the presence of 
granulomas independently predicted the need 
Table 2. Risk factors at diagnosis significantly associated with time to development of SCD, analysed with the Cox proportional hazard method





Unadjusted HR;  
95% CI; p-value
Adjusted HR;  
95% CI; p-value
Female gender, n (%) 18 (52.9) 44 (65.7) 0.64; 0.33 - 1.26; 0.20 0.59; 0.32 - 1.1; 0.1
Race, n (%)
White 8 (23.5) 13 (19.4) 1; Reference; 0.89 Not included
Black 2 (5.9) 4 (6.0) 0.88; 0.13 - 5.9 
Coloured 24 (70.6) 50 (74.6) 0.86; 0.32 - 2.32 9
Age (years), n (%)
A1, <17 4 (11.8) 47 (6.0) 1; Reference; 0.28 Not included
A2, 17 - 40 25 (73.2) 45 (67.2)
A3, >40 5 (14.7) 18 (26.9)
Perianal disease, n (%) 25 (73.5) 5 (7.5) 3.05; 1.42 - 6.56; 0.004 2.49; 1.14 - 5.41; 0.02
Location, n (%)
L1 14 (41.2) 23 (34.3) 1; Reference; 0.52 Not included
L2 7 (20.6) 21 (31.3)
L3 13 (38.2) 23 (34.3)
Extent of SB >20 cm, n (%) 18 (52.9) 43 (64.2) 1.03; 0.98 - 1.08; 0.26 Not included
Colonic segments involved (n), mean (range) 2 (0 - 3) 1 (0 - 3) 0.94; 0.8 - 1.11; 0.45 Not included
Upper GIT, n (%) 3 (8.8) 37 (4.5) 1.65; 0.5 - 5.4; 0.41 Not included
Rectal involvement, n (%) 6 (17.6) 13 (19.4) 0.96; 0.4 - 2.32; 0.93 Not included
Family history, n (%) 2 (5.9) 57 (7.5) 0.97; 0.23 - 4.04; 0.96 Not included
Current smoker*, n (%) 20 (58.8) 46 (68.7) 0.59; 0.30 - 1.18; 0.14 Not included
Appendicectomy, n (%) 3 (8.8) 2 (3.0) 1.68; 0.51 - 5.48; 0.39 Not included
>5 kg weight loss, n (%) 23 (67.6) 34 (50.7) 1.89; 0.91 - 3.86; 0.09 1.82; 0.87 - 3.8; 0.11
Steroids, n (%) 19 (55.9) 38 (56.7) 1.13; 0.57 - 2.24; 0.70 Not included
EIMs, n (%) 8 (23.5) 18 (26.9) 0.8; 0.35 - 1.72; 0.53 Not included
Granulomas, n (%) 21 (61.8) 21 (31.3) 2.33; 1.17 - 4.66; 0.02 2.3; 1.15 - 4.64; 0.02
SB = small bowel; EIMs = extraintestinal manifestations.
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Fig. 1. Kaplan-Meier curves for the development of SCD according to the presence or absence of perianal 
disease and granulomas at diagnosis in patients with B1 phenotype.
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for surgical resection. More recent publi cations have confirmed these 
findings.[22] However, many of these studies are confounded by the 
inclusion of granulomas found in surgical resection specimens as well 
as those found on endoscopic biopsies. Furthermore, analysis included 
the development of granulomas at any point over the disease course. 
Molnár et al.[23] performed a small prospective study which showed that 
at diagnosis granulomas on endoscopic biopsy were associated with a 
higher need for surgery or IMMs; these authors, however, included 
subjects with B2 and B3 disease at diagnosis. Patients with granulomas 
also had significantly higher CD activity index values at diagnosis than 
those without, a finding that was not adjusted for in analysis. Similarly, 
a paediatric study showing that endoscopic biopsy granulomas at 
diagnosis were associated with increased need for surgery included 
children with complex perianal CD.[24] To our knowledge, this study 
is the first to include only endoscopic tissue biopsy granulomas at the 
time of first diagnosis in uncomplicated B1 CD.
It is unclear how granulomas may influence CD outcomes. One 
possible explanation is an association with autophagy genetic variants. 
Autophagy is a process involved in the elimination of intracellular 
bacteria, and this pathway appears to be altered in CD. Reduced 
clearance of pathogenic bacteria may drive the chronic inflammation 
observed in these patients. Genetic variants in autophagy genes, 
notably autophagy-related gene 16-like 1 (ATG16L1) and immunity-
related GTPase M (IRGM), have been associated with susceptibility to 
CD. A recent study from Leuven evaluated surgical specimens from 
464 CD patients and found associations between granulomas and 
several autophagy gene variants.[22]
Another possible mechanism that could explain the association 
of granulomas with poor-outcome CD is the observation that 
granulomas can cause lymphatic obstruction, which could lead to 
chronic tissue oedema with subsequent irreversible fibrosis.[25]
Study limitations
Our study has a number of limitations. Firstly, we excluded patients 
with incomplete data at diagnosis. This is a potential source of 
selection bias; however, it is likely that these data were missing at 
random and not correlated with CD severity or outcome. Another 
potential source of bias is that only patients with complete follow-up 
data were included. This could introduce selection bias, as patients 
lost to follow-up may have had less severe disease than those 
who continued to be seen in our clinic. However, the cumulative 
probabilities of progressing from B1 disease at diagnosis to stenosing 
or penetrating phenotypes is almost identical to those reported in 
a large population-based study from Olmsted County, Minnesota, 
USA.[26] Furthermore, the baseline demographics (age and gender) as 
well as disease location and behaviour of our study participants were 
very similar to those reported in a New Zealand population-based 
CD cohort.[19] Finally, our study is limited by the retrospective nature 
of the analysis; in many subjects the number and site of endoscopic 
biopsies, and the number of granulomas, were not recorded.
Despite these limitations, our study has provided some valuable 
information. This is the first SA study to identify predictors of poor-
outcome CD in patients with B1 disease. This will aid the decision in 
our setting about when to risk aggressive medical therapies early in 
the disease course. As emphasised by Louis et al.[27] in a recent review, 
there are two possible errors in managing CD: overtreating patients 
who will have benign disease, and undertreating those who will go on 
to develop poor outcomes.
In our study, perianal disease and granulomas at diagnosis were 
very specific for the development of SCD over the disease course. 
Only 1% of individuals with these two predictors at diagnosis 
would be falsely classified as having SCD and therefore subjected to 
aggressive therapies unnecessarily. In addition, these two risk factors 
are routinely assessed at baseline and do not require expensive blood 
testing or genetic analysis.
Conclusion
Data from this retrospective study have shown that 34% of our cohort 
developed severe poor-outcome CD over their disease course. Our 
study has identified several factors at diagnosis of B1 CD that are 
predictive of this outcome. Notably, perianal disease and endoscopic 
biopsy granulomas were independently associated with time to the 
development of SCD. The latter is a novel finding and merits further 
prospective evaluation in different populations as a potential factor 
that accurately predicts progression from B1 disease to SCD and could 
therefore be used to identify patients who merit selection for aggressive 
medical therapies.
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